Business
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
Hoerter brings decades of pharmaceutical commercialization, leadership, and board experience to help guide MBX’s next phase of growth CARMEL, Ind., April 07,
About this update from Mbx Biosciences, Inc.
[{"type":"text","content":"Hoerter brings decades of pharmaceutical commercialization, leadership, and board experience to help guide MBX’s next phase of growth\nCARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company’s Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. “I am thrilled to welcome Steve Hoerter to the Company’s Board as an independent director,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “As a seasoned leader within the biopharmaceutical industry, Steve has scaled multiple biotech companies into revenue-generating commercial enterprises. We look forward to benefiting from his contributions as we advance MBX Biosciences’ growing pipeline of programs in endocrine and metabolic disorders, including hypoparathyroidism, post-bariatric hypoglycemia, and obesity.” Steve Hoerter said, “It is an exciting time to join the MBX Biosciences’ Board as an independent director and I look forward to joining such an esteemed group of industry leaders. The Company’s portfolio of innovative Precision Endocrine Peptides™ and its experienced management team represent clear competitive advantages for the Company, and I am excited to collaborate with this group as we endeavor to deliver differentiated endocrine and metabolic compounds to underserved patients.” Mr. Hoerter previously served as President, Chief Executive Officer and Director of Deciphera Pharmaceuticals until its $2.4 billion acquisition by Ono Pharmaceutical in 2024. Prior to leading Deciphera, Mr. Hoerter served in senior commercial leadership roles at Agios Pharmaceuticals, Clovis Oncology, Roche and Genentech. Mr. Hoerter currently serves as a Board member at ORIC Pharmaceuticals and as a member of its Audit and Compensation committees, and as a board member at C4 Therapeutics. Mr. Hoerter’s previous board experience includes Constellation Pharmaceuticals, which was acquired by Morphosys in 2021 for $1.7 billion...